Sippican Capital Advisors increased its stake in Johnson & Johnson (NYSE:JNJ) by 2.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,669 shares of the company’s stock after buying an additional 95 shares during the period. Sippican Capital Advisors’ holdings in Johnson & Johnson were worth $485,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the company. Sandhill Capital Partners LLC raised its stake in Johnson & Johnson by 2.7% in the fourth quarter. Sandhill Capital Partners LLC now owns 8,997 shares of the company’s stock valued at $1,037,000 after buying an additional 239 shares during the last quarter. Intact Investment Management Inc. raised its stake in Johnson & Johnson by 7.6% in the fourth quarter. Intact Investment Management Inc. now owns 156,800 shares of the company’s stock valued at $18,070,000 after buying an additional 11,100 shares during the last quarter. Continental Advisors LLC raised its stake in Johnson & Johnson by 28.9% in the fourth quarter. Continental Advisors LLC now owns 22,300 shares of the company’s stock valued at $2,569,000 after buying an additional 5,000 shares during the last quarter. Guardian Capital Advisors LP raised its stake in Johnson & Johnson by 2.5% in the fourth quarter. Guardian Capital Advisors LP now owns 90,314 shares of the company’s stock valued at $10,554,000 after buying an additional 2,235 shares during the last quarter. Finally, Zurich Insurance Group Ltd FI raised its stake in Johnson & Johnson by 8.0% in the fourth quarter. Zurich Insurance Group Ltd FI now owns 439,086 shares of the company’s stock valued at $50,587,000 after buying an additional 32,565 shares during the last quarter. Institutional investors and hedge funds own 66.06% of the company’s stock.

Shares of Johnson & Johnson (NYSE JNJ) traded up 0.7369% during midday trading on Friday, hitting $134.0708. The company’s stock had a trading volume of 2,026,713 shares. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $137.08. The stock’s 50 day moving average is $133.18 and its 200-day moving average is $126.16. The firm has a market cap of $359.85 billion, a P/E ratio of 22.6854 and a beta of 0.78.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating the consensus estimate of $1.79 by $0.04. The firm had revenue of $18.84 billion during the quarter, compared to the consensus estimate of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.74 earnings per share. Equities analysts predict that Johnson & Johnson will post $7.18 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 2.52%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 56.76%.

TRADEMARK VIOLATION WARNING: “Sippican Capital Advisors Has $485,000 Stake in Johnson & Johnson (NYSE:JNJ)” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.watchlistnews.com/sippican-capital-advisors-has-485000-stake-in-johnson-johnson-nysejnj/1476002.html.

JNJ has been the topic of several research analyst reports. Morgan Stanley upped their price objective on Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Wednesday, July 5th. BidaskClub lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 1st. Vetr lowered Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.54 price objective on the stock. in a research note on Monday, May 1st. Jefferies Group LLC restated a “hold” rating and issued a $140.00 price objective on shares of Johnson & Johnson in a research note on Friday, June 16th. Finally, Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Friday, July 21st. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $133.72.

In other news, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now directly owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the transaction, the vice president now directly owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.